Recent fluctuations in the consensus price target for NASDAQ:HALO reflect changing analyst expectations, with a current average price target of $74.5.Halozyme's acquisition of Elektrofi, Inc. for an upfront payment of $750 million is set to enhance its drug delivery offerings and influence its outlook for 2025.Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that specializes in drug delivery technology. Its ENHANZE platform is renowned for enabling the subcutaneous delivery of injec ...